Business Context and Reporting Period
This Form 8-K is filed by PharmAthene, Inc. (not Altimmune, Inc.) on January 7, 2015, reporting a significant legal development in its ongoing litigation with SIGA Technologies, Inc. regarding the smallpox antiviral Tecovirimat.
Key Financial Metrics
The filing does not report standard operating metrics such as revenue, profit, cash flow, or margins for a specific period. The primary financial data relates to a potential legal award:
- Contract Damages: Approximately $113 million in lump sum expectation damages.
- Total Estimated Award: In excess of $190 million, including pre-judgment interest (from 2006) and partial reimbursement of legal fees.
- Liquidity Context: SIGA has stated it lacks sufficient cash to satisfy the award and is under federal bankruptcy protection.
Material Changes and Legal Status
The Delaware Court of Chancery issued an Order directing PharmAthene to submit a Revised Proposed Judgment reflecting the damages. While the Company submitted a draft on January 9, 2015, the final amount remains subject to court approval and potential appeal by SIGA to the Delaware Supreme Court. The automatic stay on enforcement actions due to SIGA's bankruptcy has been lifted solely to allow the entry of a money judgment and appellate proceedings, but collection remains subject to further Bankruptcy Court proceedings.
Outlook, Risks, and Contingencies
Management emphasizes significant uncertainty regarding the realization of the award. There are no assurances that payments will be received from SIGA. Additional risks include:
- Collection Risk: SIGA's bankruptcy status and lack of cash may prevent payment.
- Appeal Risk: The decision could be reversed, remanded, or changed on appeal.
- Funding Risks: Future government funding for product candidates (Valortim, rBChE, SparVax) is unlikely. Recent government actions include a partial termination of the SparVax contract and uncertainty regarding NIAID contract options.
- Development Risks: Significant non-clinical and clinical work remains for all product candidates.
Investor Verification Checklist
- Verify the final approved judgment amount and interest calculation by the Delaware Court of Chancery.
- Monitor SIGA's bankruptcy proceedings to assess the feasibility of collecting the $190 million+ award.
- Track the status of SIGA's appeal to the Delaware Supreme Court.
- Review updates on government funding decisions for SparVax, Valortim, and rBChE.
- Confirm the Company's current cash position and runway given the lack of immediate revenue from the litigation award.